Peter MacCallum Cancer Centre

North Melbourne 3051

2 studies enrolling now · 3 studies all time

What they study most

Advanced Melanoma, Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Hormone Refractory Prostatic Cancer, Immune Checkpoint Inhibitor, Immunotherapy, Inhibitory Checkpoint Molecule, Prostate Cancer Recurrent

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer — Completed